Clinical Trials Logo
  1. Home
  2. Toxic Epidermal Necrolysis
  3. NCT02574988

Severe Cutaneous Adverse Reactions in Thailand — ThaiSCAR  

Toxic Epidermal Necrolysis Clinical Trial

Official title:
The Multicenter Registry of Patients With Severe Cutaneous Adverse Reactions Among Tertiary Medical Institutes in Thailand

Clinical Trial Summary

The multicenter registry of patients with severe cutaneous adverse reactions among tertiary medical institutes in Thailand to study clinical characteristics, etiologies, therapeutic outcomes, quality of life, and the values of in vitro drug allergy diagnosis for the confirmation of the causative drugs

Clinical Trial Description

Patients with severe cutaneous adverse reactions (Steven-Johnson Syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, acute generalized exanthematous pustulosis, and generalized bullous fixed drug eruption) among six tertiary medical institutes in Thailand will be recruited to study clinical characteristics, etiologies, therapeutic outcomes, quality of life, and the values of using laboratory techniques for the confirmation of the causative drugs ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02574988
Study type Observational [Patient Registry]
Source Chulalongkorn University
Contact Jettanong Klaewsongkram, MD
Phone 02-2564152
Email Jettanong.K@chula.ac.th
Status Recruiting
Phase
Start date January 2014
Completion date December 2020
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04711200 - LYell SYndrome MEsenchymal Stromal Cells Treatment Phase 1/Phase 2
Completed NCT01696500 - Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. Phase 3
Terminated NCT02037347 - Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis Phase 1/Phase 2
Withdrawn NCT02795143 - Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study N/A
Withdrawn NCT02319616 - Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis Phase 1/Phase 2
Recruiting NCT06119490 - Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis Early Phase 1
Withdrawn NCT00372723 - Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN) Phase 2
Not yet recruiting NCT03585946 - Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis